Search Results (242)

Background/Objectives: Endovascular aneurysm repair (EVAR) is currently the preferred method for treating abdominal aortic aneurysms (AAA) due to lower perioperative morbidity and mortality compared with open aortic repair (OAR). However, anatomical limitations such as narrow or tortuous iliac arteries may preclude EVAR. The low-profile Altura^® stent graft (LPSG) was designed to overcome these limitations. This study aimed to compare the outcomes of Altura^® low-profile endografts with standard-profile stent grafts (SPSGs) in AAA treatment. Methods: This single-center, retrospective, case-matched study included 30 patients treated with Altura^® LPSG and 30 matched controls who underwent SPSG implantation between July 2021 and February 2023. Demographic, anatomical, operative, and postoperative parameters were analyzed. Follow-up was performed at 3, 6, and 12 months using ultrasound and computed tomography angiography (CTA). Results: Patients in the LPSG group more frequently had narrow access vessels (<6 mm, 46.7% vs. 3.3%, p = 0.001). The mean procedure time was shorter in the LPSG group (80 vs. 90 min, p = 0.04), and hospital stay was reduced (3 vs. 4 days, p = 0.03). No 30-day mortality occurred in either group. At 12 months, no aneurysm rupture, graft infection, or aneurysm-related death was observed. The rate of secondary interventions was comparable between groups. Conclusions: The low-profile Altura^® stent graft provides a safe and effective option for AAA patients with narrow access vessels. Its bilateral parallel configuration and lack of gate cannulation simplify EVAR, shorten procedure time, and may be especially beneficial in emergency or anatomically challenging cases. Further prospective studies are warranted to confirm these findings. Full article

Background: Coronary artery disease (CAD) remains a significant health challenge, placing a heavy burden on people and healthcare systems worldwide. Objectives: This narrative review aims to provide a comprehensive overview of recent advancements in the diagnosis, intervention, and pharmacological management of CAD, with a focus on emerging technologies shaping its future. Methods: This is a narrative review that synthesises information from diverse sources, including clinical trials, systematic reviews, meta-analyses, and preclinical studies, to provide a comprehensive overview of the current landscape and emerging trends in CAD management. The literature included in this review was sourced from original research articles and review papers published between January 2010 and December 2025. Results: Early detection has been transformed by non-invasive imaging, such as PCAT, and the addition of invasive and non-invasive FFR technology enables quicker and more accurate diagnoses. Biomarkers, such as high-sensitivity troponin, have further improved the precision of acute coronary syndrome detection, enhancing early intervention. In interventional cardiology, new-generation drug-eluting stents (DESs) have lowered restenosis rates, whereas robotic-assisted percutaneous coronary intervention (PCI) offers precision and reduced operator radiation exposure. Furthermore, the efficacy of drug-coated balloons (DCBs) has been established in the management of in-stent restenosis, and their application in de novo coronary lesions and bifurcation anatomy remains promising. Looking ahead, nanomedicine promises targeted plaque reduction and vascular repair, while 3D-bioprinted blood vessels offer durable, biocompatible grafts for surgical applications. Pharmacological developments, including modern cholesterol-lowering drugs, have also been crucial in achieving cholesterol targets. Conclusions: Despite significant advancements in diagnosis, intervention, and pharmacotherapy, several critical challenges remain, including the need for validated biomarkers and imaging modalities to identify vulnerable atheroma before symptoms arise. Continued research is essential to improve patient outcomes and address the global burden of CAD. Full article

Background/Objectives: Endovascular aneurysm repair (EVAR) is the standard treatment for abdominal aortic aneurysms, but the risk of endoleak compromises its effectiveness. Type IA endoleak, stemming from an inadequate proximal seal, is the most critical complication associated with the highest risk of rupture. Current preoperative planning relies on static anatomical measurements from computed tomography angiography that fail to predict seal failure due to dynamic biomechanical forces. This study aimed to retrospectively validate the predictive accuracy of a novel physics-informed digital twin and artificial intelligence (AI) model for predicting type IA endoleak risk compared to conventional static planning methods. Methods: This was a retrospective, single-center proof-of-concept validation study involving 15 patients who underwent elective EVAR (5 with confirmed type IA endoleak and 10 without type IA endoleak). A patient-specific digital twin was created for each case to simulate stent-graft deployment and capture the dynamic biomechanical interaction with the aortic wall. A logistic regression AI model processed over 16,000 biomechanical measurements to generate a single, objective metric of the endoleak risk index (ERI). The predictive performance of the ERI (using a cutoff of 0.80) was assessed and compared against a 1:3 propensity score-matched conventional control group (n = 45) who received traditional anatomical-based planning. Results: The mean ERI was significantly higher in the endoleak-positive group (0.85 ± 0.10) compared to the endoleak-negative group (0.39 ± 0.11) (p = 0.011). The digital twin/AI model demonstrated superior predictive capability, achieving an overall accuracy of 80% (95% CI: 51.9–95.7) and an area under the curve (AUC) of 0.85 (95% CI: 0.58–0.99). Crucially, the model achieved a sensitivity of 100% and a negative predictive value (NPV) of 100%, correctly identifying all high-risk cases and ruling out endoleak in all low-risk cases. In stark contrast, the matched conventional planning group achieved an overall accuracy of only 51.1% and an AUC of 0.54. Conclusion: This physics-informed digital twin and AI framework successfully validated its capability to accurately and objectively predict the risk of type IA endoleak following EVAR. The derived ERI offers a significant quantitative advantage over traditional static anatomical measurements, establishing it as a highly reliable safety tool (100% NPV) for ruling out endoleak risk. This technology represents a critical advancement toward personalized EVAR planning, enabling surgeons to proactively identify high-risk anatomies and adjust treatment strategies to minimize post-procedural complications. Further large-scale, multicenter prospective trials are necessary to confirm these findings and support clinical adoption. Full article

Background/Objectives: Long-term outcomes of patients with left main coronary artery (LMCA) disease and diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) are incompletely investigated. The aim of this study was to assess the 10-year clinical outcomes after PCI according to diabetic status and antidiabetic therapy in patients with LMCA. Methods: This study represents a pooled analysis of two randomized trials (n = 1257 patients) on LMCA PCI focused on the prespecified subgroups of diabetic patients. Patients were categorized in groups according to the diabetic status and antidiabetic therapy (oral drugs or insulin therapy). The primary endpoint was 10-year all-cause mortality. Results: Overall, 361 patients had DM (246 patients on oral antidiabetic drugs and 115 patients on insulin therapy) and 896 patients had no DM. At 10 years, 477 patients died: 291 nondiabetic patients (35.7%), 111 diabetic patients (49.5%) on oral antidiabetic drugs and 75 diabetic patients (70.0%) on insulin therapy (hazard ratio [HR] = 1.57, 95% confidence interval [1.26–1.96]; p < 0.001 for diabetic patients on oral antidiabetic drugs vs. nondiabetic patients; HR = 2.80 [2.17–3.61]; p < 0.001 for diabetic patients on insulin therapy vs. nondiabetic patients; HR = 1.78 [1.33–2.39]; p <0.001 for diabetic patients on insulin therapy vs. diabetic patients on oral antidiabetic drugs). The 10-year incidence of myocardial infarction was higher in diabetic patients on insulin therapy (10.0%) versus diabetic patients on oral antidiabetic drugs (3.0%). There were no significant differences between the groups regarding the 10-year incidence of definite stent thrombosis, coronary artery bypass graft surgery, repeat PCI or stroke. Conclusions: In patients with LMCA disease undergoing PCI, DM was associated with a higher 10-year incidence of all-cause mortality than patients without DM with the worst outcomes observed in diabetic patients on insulin therapy. Full article

Type B aortic dissection (TBAD) requires management tailored to the disease phase and clinical presentation, with the subacute period representing a favorable window for endovascular intervention due to improved procedural safety and remodeling potential. We report the case of a 38-year-old male with hypertension, dyslipidemia, and bicuspid aortic valve disease who presented one month after symptom onset with persistent chest pain and progressive bilateral lower-limb numbness. Clinical examination suggested early spinal cord ischemia, while laboratory tests demonstrated acute hepatic and renal dysfunction. CT angiography revealed a subacute TBAD with a markedly expanded false lumen and near-complete compression of the true lumen, resulting in visceral, renal, and potential spinal malperfusion. Given the high-risk anatomy and evolving organ dysfunction, a staged hybrid strategy was undertaken. A left carotid–subclavian bypass was performed to secure proximal landing for endovascular repair, followed the next day by thoracic endovascular aortic repair (TEVAR) using two thoracic stent grafts. Postoperative recovery was favorable, with rapid resolution of neurological symptoms and normalization of hepatic and renal parameters, allowing discharge on postoperative day seven. This case underscores the importance of early recognition of malperfusion and timely hybrid intervention in subacute TBAD with severely compressed true lumen, demonstrating excellent early clinical outcomes. Full article

Peripheral artery disease (PAD) leads to reduced blood flow, primarily affecting the vessels of lower extremities. Symptoms include pain, cramping and reduced functional capacity, and patients are also at increased risk of cardiovascular complications and mortality. Postoperative medical management in PAD patients includes the use of antiplatelet and antithrombotic medications, which help to prevent postoperative graft and stent thrombosis and associated adverse effects. Despite extensive research, there is little consensus on the best strategy or medication regimen for patients with PAD or on monitoring strategies for the antithrombotic therapies. Thromboelastography, with the adjunct of platelet function assessment, is well established for providing real-time assessment of coagulation and platelet function in patients undergoing cardiovascular surgery or cardiovascular procedures. TEG^® PlateletMapping^® assays can assess hypercoagulable changes in pre- and post-intervention in cardiovascular patients, including in patients with PAD and help physicians guide antithrombotic treatments after revascularization. The use of thromboelastography with platelet function analysis provides an opportunity to tailor antithrombotic therapy and personalize care in patients with PAD, which could be integral to improving limb salvage and preventing adverse events in these patients. Full article

Background/Objective: Endovascular aneurysm repair (EVAR) using Aorfix (Lombard Medical, Inc., Irvine, CA, USA)^TM has shown excellent outcomes, even in cases of abdominal aortic aneurysm with highly angulated aortic necks (≥60°). However, long-term outcomes for Japanese patients remain unknown. In this study, we aimed to investigate the performance of Aorfix^TM in Japanese patients with highly angulated aortic necks. Methods: Among 114 patients in whom Aorfix^TM was used for EVAR at a single institution from October 2014 to October 2021, 105 patients without rupture or infection were retrospectively reviewed. They were classified into the following two groups: those with proximal neck angulations of ≥60° and <60°. Endpoints included technical success, long-term survival, freedom from aneurysm-related mortality, and freedom from reintervention. Results: Among 105 cases reviewed, 54 and 51 had proximal neck angulations of <60° and ≥60°, respectively. The <60° and ≥60° groups had a mean neck angulation of 30.7° (median 30°, range 10–56°) and 80.3° (median 77°, range 60–110°), respectively. The ≥60° group had significantly increased operation time (p = 0.034), volume of contrast agent used during the operation (p = 0.0301), and duration of fluoroscopy during the operation (p < 0.0001); however, the rates of additional renal artery stenting, cuff placement, and access site complications did not differ between the groups. There were also no differences in the incidence of aneurysm enlargements, secondary intervention, and endoleaks incidence. Conclusions: EVAR with Aorfix^TM achieved satisfactory results in Japanese patients with severe and mild/moderate proximal neck angulation. Full article

Background: This study examines the use of the E-liac stent-graft system for the endovascular treatment of aortoiliac or isolated common iliac aneurysms. Methods: Consecutive patients between January 2014 and December 2024 were included. Data on patient characteristics, clinical presentation, lesion features, procedural aspects, and follow-up outcomes were collected and examined. Complications during the perioperative period and subsequent reinterventions were also documented. Results: A total of 81 patients met the inclusion criteria (65 men, 80.2%, median age 71.2 ± 11.43 (range 61–86 years). Technical success was achieved in all cases. A total of 97 internal iliac arteries were revascularized; in 54 cases (66.7%), the endovascular technique was EVAR + unilateral iliac branch device (IBD), in 16 cases (19.8%), it was EVAR + bilateral IBDs, and unilateral isolated IBD was conducted in 11 (13.6%) patients. The median patient follow-up time was 64.7 months (range 1–120). During follow-up, the mortality rate was 22.2%, with an iliac branch patency of 90.1%. Buttock claudication was observed in five (6.2%) patients and nerve ischemia in one (1.2%). One type I endoleak (1.2%) occurred following endovascular treatment of an isolated common iliac artery aneurysm, and three type II endoleaks (3.7%) were observed; none of them were associated with aneurysm sac enlargement. Three type III endoleaks (3.7%) occurred due to disconnection of the iliac branch from the extension of the concomitant EVAR. Conclusions: This long-term study, with 11 years of follow-up, reports outcomes with the E-liac stent-graft for the treatment of aorto-iliac or iliac aneurysms and demonstrates that it can be safely applied with low mortality and reintervention rates, and high patency rates. Full article

Background: Urinary tract infections (UTIs) are the most common infections among kidney transplant recipients, with prevalence rates ranging from 12% to 75% in studies from North America and Australia and from 4.5% to 85% in the Middle East. These infections can significantly impact graft survival and patient quality of life, increasing the risk of hospitalization, morbidity, and mortality. Escherichia coli is the leading cause of UTIs in transplant patients, but multidrug-resistant (MDR) pathogens are a growing concern, especially in Saudi Arabia. Several factors, including advanced age, female gender, and use of urinary catheters, contribute to post-transplant UTIs. This study focuses on the Saudi population, aiming to assess the prevalence, risk factors, and treatment strategies for recurrent and multidrug-resistant UTIs in kidney transplant recipients. Methods: This retrospective cohort study reviewed the medical records of kidney transplant patients at King Faisal Specialist Hospital & Research Center, Jeddah, in addition to data from King Fahad Hospital, Madinah, Saudi Arabia, between March and May 2022. Adult patients (≥18 years) who developed recurrent UTIs within two years post-transplant were included, while those with one or no UTI episode or incomplete records were excluded. Results: Seventy-five of 491 screened patients (15.3%) experienced recurrent UTIs, contributing to a total of 219 episodes. Klebsiella pneumoniae was the most frequent pathogen, isolated in 94 episodes (42.9%). Key risk factors for recurrence included complicated UTIs (OR = 4.60, p = 0.005), multidrug-resistant organisms (MDROs) (OR = 3.14, p = 0.021), and ureteric stents (OR = 4.07, p = 0.042). Carbapenems were primarily used for complicated UTIs, while cephalosporins and penicillins were used for uncomplicated infections. A significant post-UTI rise in serum creatinine was observed (p < 0.001). Conclusions: Recurrent UTIs predominantly caused by K. pneumoniae are common in kidney transplant recipients, particularly in patients over 45, with multidrug-resistant organisms, or with ureteric stents. While a direct causal link to graft loss was not established, these infections can lead to increased creatinine levels, hospitalizations, and healthcare costs and increased carbapenem use. These findings highlight the critical need for institution-specific antimicrobial stewardship programs focused on infection prevention and optimized antibiotic use to improve outcomes in this vulnerable population. Full article

Herniation of the transplanted ureter into the inguinal canal is an exceptionally rare complication following renal transplantation. Most cases present as delayed-onset obstructions, typically occurring more than one year post-transplant and often involving the ipsilateral inguinal canal. We presented the case of a 49-year-old male kidney transplant recipient who developed obstructive uropathy due to herniation of the graft ureter into the ipsilateral inguinal canal. Diagnosis was confirmed by computed tomography (CT), which proved superior to ultrasonography in delineating the ureteral course. A JJ ureteral stent was successfully placed, followed by inguinal hernia repair using the Lichtenstein technique. The postoperative course was uneventful, with complete resolution of symptoms and preservation of graft function. Transplanted ureteral herniation is a rare but important cause of late post-transplant obstruction. Cross-sectional imaging, particularly CT, offers greater diagnostic accuracy than ultrasound alone in identifying ureteral displacement. When feasible, primary ureteral stenting may obviate the need for nephrostomy, thereby reducing patient morbidity. Full article

Background: Coronary artery bypass grafting (CABG) remains a standard revascularization strategy for patients with advanced coronary artery disease (CAD). However, a considerable proportion of patients experience recurrent ischemia requiring repeat revascularization. Residual platelet reactivity (RPR) and dyslipidemia are recognized as key factors contributing to graft failure and disease progression. Methods: This observational study was conducted at a tertiary cardiology center in Kazakhstan. A total of 195 post-CABG patients who underwent repeat coronary angiography between 2023 and 2024 recruitment period for recurrent ischemic symptoms within 6–36 months after surgery were included. Clinical characteristics, comorbidities, lipid profiles, and antiplatelet response were analyzed. RPR was measured using the VerifyNow P2Y12 assay when available. Dyslipidemia was defined according to the 2019 and 2021 European guidelines. Results: Elevated RPR was identified in 45% of patients (n = 90) despite dual antiplatelet therapy (p < 0.01). Poor lipid control was frequent among those who underwent repeat percutaneous coronary intervention (PCI), particularly elevated levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol (p < 0.05). Both elevated RPR and dyslipidemia were independently associated with native coronary disease progression and graft failure (RPR: OR = 2.8; 95% CI 1.4–5.6; p = 0.003; dyslipidemia: OR = 2.2; 95% CI 1.1–4.3; p = 0.02). The use of ezetimibe was independently associated with a significantly lower risk of repeat stenting (OR = 0.12; 95% CI 0.02–0.75; p = 0.023). Smokers were younger, had lower blood pressure, and less frequently presented with diabetes or chronic kidney disease, demonstrating a pattern consistent with the “smoker’s paradox.” Conclusions: Residual platelet reactivity and dyslipidemia are common and clinically relevant predictors of repeat revascularization after CABG. Optimization of antiplatelet and lipid-lowering therapy should be prioritized in secondary prevention for this high-risk population. These findings are particularly important in Kazakhstan, where post-CABG management strategies warrant further improvement. Full article

Background and Clinical Significance: Concomitant severe aortic stenosis (AS) and abdominal aortic aneurysm (AAA) in elderly patients presents a significant therapeutic challenge. While transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR) have become established minimally invasive treatments for high-risk patients, simultaneous management of both conditions remains rare. Case Presentation: We report the first documented case in Serbia of a simultaneous TAVR and EVAR in a 75-year-old male with severe symptomatic AS and AAA. The patient had a history of hypertension, diabetes mellitus, atrial fibrillation, prior radiofrequency pulmonary vein ablation, and pacemaker implantation. Echocardiography demonstrated severe AS with a transvalvular gradient of 116/61 mmHg, an aortic valve area of 0.6 cm², and a left ventricular ejection fraction of 30–35%. Coronary angiography revealed 50–60% stenosis of the right coronary artery. Following evaluation by a multidisciplinary Heart and Vascular Team, a combined procedure was performed under general anesthesia via bilateral femoral access. TAVR with a Medtronic Evolut R valve was successfully deployed, followed by EVAR with satisfactory stent graft positioning and angiographic results. The patient’s postoperative course was uneventful, and he was discharged on the ninth day. At six-month follow-up, echocardiography showed optimal valve function, and CT identified a type II endoleak, which was managed conservatively. Conclusions: This case demonstrates the feasibility and safety of simultaneous TAVR and EVAR in a high-risk elderly patient, emphasizing the importance of careful preoperative planning and a coordinated multidisciplinary approach. Further studies are warranted to establish standardized guidelines for the management of patients with coexisting severe AS and AAA. Full article

Three-dimensional printing has emerged as a promising technology in endovascular surgery for the production of patient-specific stent-grafts. Thermoplastic polyurethane (TPU) is widely used for this purpose due to its favourable biocompatibility, hemocompatibility, and mechanical properties. However, its long-term stability under physiological conditions remains uncertain. This study evaluates the ageing behaviour of 3D-printed TPU stent-grafts under accelerated oxidative conditions (20% H₂O₂–0.1 M CoCl₂) over three months, corresponding to approximately 45 months in vivo, and during three months in hydrolytic (0.1 M NaOH) conditions. Mechanical, physicochemical, thermal, and surface properties were periodically analysed. Differential scanning calorimetry revealed a decrease in crystallisation enthalpy of 41% and a reduction in melting enthalpy of 29% after hydrolytic ageing, whereas no decrease was observed after oxidative ageing. Despite these chemical changes, size exclusion chromatography indicated minimal chain scission. However, spectroscopy and microscopy showed minor chain scission and additive migration (antioxidant and lubricant). Nevertheless, tensile testing highlighted that mechanical performance remained within clinically acceptable ranges. These findings demonstrate that 3D-printed TPU vascular implants retain essential properties under prolonged simulated ageing, supporting their safety and durability for vascular applications. Full article

Background and Objectives: Pulmonary sequestration (PS) is a rare congenital lung malformation. In adults, intralobar disease with recurrent infection or hemoptysis predominates. Cross-sectional imaging (CTA/MRA) is central to mapping the aberrant systemic supply; catheter angiography is used when noninvasive imaging is inconclusive or when an endovascular procedure is planned. We aimed to synthesize adult PS cases treated with endovascular or hybrid approaches and to summarize case selection, techniques, and outcomes. Methods: We conducted a PRISMA-2020-informed systematic review. We searched PubMed and Scopus from 1 January 2000 to 31 May 2025. Two reviewers extracted data independently; due to heterogeneity, we performed a narrative synthesis and a JBI-adapted qualitative risk-of-bias appraisal. Eligible studies enrolled adults (≥18 years) with imaging-confirmed PS treated with embolization, stent-graft exclusion, or hybrid therapy; prespecified outcomes included technical and clinical success, complications, recurrence, and re-intervention. The review was not registered. Results: Of 93 records screened, 41 publications reporting 48 adults were included. Twenty-five patients were managed endovascularly and 23 with hybrid therapy. Intralobar sequestration predominated (36/48); feeding arteries most often arose from the descending thoracic aorta (28/48). Complications were reported in 10 cases, mostly minor; three embolization cases required re-intervention. Conclusions: Endovascular therapy is useful for selected anatomies and urgent bleeding control, while hybrid strategies may benefit large, complex, or aneurysmal feeding arteries. The evidence base is limited to small case reports/series with heterogeneous outcome definitions and follow-up, precluding quantitative synthesis. Standardized outcome definitions, structured follow-up, and prospective registries are needed. Full article

Cardiovascular diseases remain the leading cause of death worldwide and are often managed through invasive surgical procedures such as heart transplantation, ventricular assist device implantation, coronary artery bypass grafting, and stent placement. However, significant unmet medical needs persist in this field. The development of pharmaceutical agents using non-invasive delivery strategies is therefore of critical importance. Current treatments often target peripheral tissues or organs—such as capillary endothelial cells, vascular smooth muscle, and renal tubules—to reduce cardiac workload by lowering blood pressure. However, effective drug delivery directly to the myocardium continues to pose a significant challenge. For conditions such as congestive heart failure (CHF) and myocardial infarction (MI), targeted delivery of therapeutic agents to the heart is essential. In this perspective review, I discuss the potential and emerging strategies for non-invasive cardiac drug delivery, focusing on receptor-mediated endocytosis and transcytosis using nanoparticle-based delivery systems that have frequently been employed for targeting the brain or cancer cells although their use for cardiac delivery remains largely unexplored. Full article